Latest Ratios: P/E Ratio -111.7x · EV/EBITDA N/A · ROE -3.4%. (1995–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $1.4B | $1.2B | $1.2B | $710M | $773M | $1.4B | $1.1B | $315M | $196M | $80M | $20M |
| Enterprise Value | $1.3B | $1.2B | $1.1B | $716M | $797M | $1.4B | $1.0B | $310M | $165M | $73M | $22M |
| P/E Ratio → | -111.72 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 14.18 | 12.23 | 14.54 | 9.37 | 10.14 | 12.04 | 22.65 | 11.50 | 9.91 | 7.22 | 2.47 |
| P/B Ratio | 3.65 | 3.16 | 3.43 | 2.10 | 2.12 | 2.99 | 5.31 | 3.79 | 4.53 | 7.89 | 6.43 |
| P/FCF | 128.29 | 110.58 | 229.80 | — | — | — | 578.77 | 585.26 | 105.83 | 172.55 | — |
| P/OCF | 67.84 | 58.48 | 141.85 | — | — | — | 167.19 | 259.58 | 83.29 | 131.54 | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 12.07 | 13.75 | 9.44 | 10.46 | 11.68 | 21.00 | 11.32 | 8.35 | 6.62 | 2.65 |
| EV / EBITDA | — | — | 738.05 | — | 56.82 | — | 581.76 | 202.73 | 41.23 | — | — |
| EV / EBIT | — | — | — | — | — | — | — | 402.30 | — | — | — |
| EV / FCF | — | 109.16 | 217.27 | — | — | — | 536.63 | 575.79 | 89.24 | 158.10 | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 64.6% | 64.6% | 65.3% | 61.6% | 61.5% | 24.2% | 57.1% | 67.6% | 68.5% | 61.2% | 58.1% |
| Operating Margin | -12.6% | -12.6% | -8.7% | -30.9% | -7.8% | -29.5% | -6.9% | -2.9% | 18.5% | -9.6% | -59.0% |
| Net Profit Margin | -12.6% | -12.6% | -24.5% | -87.6% | -183.4% | -7.5% | 5.5% | -6.1% | 16.5% | -22.8% | -83.6% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -3.4% | -3.4% | -5.9% | -18.9% | -33.1% | -2.6% | 1.9% | -2.6% | 12.3% | -37.9% | -105.6% |
| ROA | -3.0% | -3.0% | -5.0% | -15.4% | -27.9% | -2.3% | 1.6% | -2.4% | 11.3% | -25.1% | -67.7% |
| ROIC | -2.8% | -2.8% | -1.7% | -4.8% | -1.1% | -9.4% | -2.5% | -1.3% | 34.5% | -19.7% | -68.4% |
| ROCE | -3.2% | -3.2% | -1.9% | -6.0% | -1.3% | -9.6% | -2.2% | -1.2% | 13.5% | -12.1% | -55.6% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.05 | 0.05 | 0.09 | 0.10 | 0.12 | 0.06 | 0.05 | 0.02 | — | — | 0.90 |
| Debt / EBITDA | — | — | 19.70 | — | 3.11 | — | 6.42 | 0.89 | — | — | — |
| Net Debt / Equity | — | -0.04 | -0.19 | 0.02 | 0.07 | -0.09 | -0.39 | -0.06 | -0.71 | -0.66 | 0.45 |
| Net Debt / EBITDA | — | — | -42.57 | — | 1.73 | — | -45.68 | -3.33 | -7.66 | — | — |
| Debt / FCF | — | -1.42 | -12.53 | — | — | — | -42.14 | -9.47 | -16.59 | -14.45 | — |
| Interest Coverage | -3.46 | -3.46 | -9.92 | -14.15 | -15.54 | -63.19 | -199.28 | 154.00 | -5000.00 | -4.68 | -24.26 |
Net cash position: cash ($33M) exceeds total debt ($18M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.94 | 5.94 | 4.54 | 2.86 | 3.11 | 2.95 | 7.37 | 3.11 | 19.37 | 6.56 | 4.08 |
| Quick Ratio | 4.63 | 4.63 | 3.66 | 1.83 | 2.32 | 2.28 | 6.62 | 1.68 | 17.56 | 5.34 | 2.53 |
| Cash Ratio | 3.87 | 3.87 | 3.19 | 1.05 | 1.41 | 1.64 | 5.81 | 0.83 | 15.81 | 4.40 | 1.24 |
| Asset Turnover | — | 0.24 | 0.21 | 0.18 | 0.17 | 0.22 | 0.20 | 0.29 | 0.43 | 0.91 | 1.04 |
| Inventory Turnover | 1.13 | 1.13 | 0.99 | 2.22 | 0.84 | 3.19 | 1.78 | 0.80 | 1.77 | 2.32 | 1.96 |
| Days Sales Outstanding | — | 30.17 | 40.68 | 89.77 | 162.47 | 71.12 | 60.77 | 71.28 | 56.30 | 33.81 | 52.96 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | 0.2% | 0.1% | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | 0.8% | 0.9% | 0.4% | — | — | — | 0.2% | 0.2% | 0.9% | 0.6% | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 2.2% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 2.4% | 0.1% | 0.0% |
| Shares Outstanding | — | $49M | $46M | $44M | $42M | $39M | $27M | $19M | $16M | $13M | $13M |
Clinical trial funding dependency
Based on reported figures, BLFS trades at a price-to-sales multiple of 14.56, which suggests that investors are pricing in significant future growth despite the company's current lack of GAAP profitability and the inherent volatility associated with its transition toward a pure-play cell processing consumables business model.
The forward P/E of 201.19 indicates that the market is heavily discounting near-term earnings in favor of long-term scaling potential within the CGT sector. This valuation premium appears to rely on the assumption that the company's regulatory moat will translate into sustained, high-margin revenue growth as clinical trials progress toward commercialization.
According to recent financial statements, BLFS maintains a robust gross margin profile, consistently exceeding 60% in most periods, which highlights the strong pricing power inherent in its proprietary biopreservation media formulations despite the broader operational challenges and negative operating margins that continue to weigh on profitability.
While the gross margin remains a bright spot, the operating margin of -12.61% suggests that the business is currently burdened by excessive fixed costs and R&D overhead. Investors should monitor whether the recent divestiture of lower-margin freezer assets will successfully allow the company to achieve operating leverage in the coming quarters.
As reported in quarterly filings, the company's asset turnover remains low at 0.07, reflecting the operational friction and inventory management challenges inherent in the transition to a consumables-focused model, where the cash conversion cycle has historically been volatile, reaching as high as 551 days in 2024Q2.
The elevated days inventory outstanding (DIO) suggests that the company is carrying significant stock, which may be a strategic buffer or a sign of inefficient demand forecasting. Improving these efficiency metrics is critical for the company to demonstrate that its leaner business model can generate superior returns on invested capital.
Based on reported figures, BLFS has successfully reduced its total debt to a conservative debt-to-equity ratio of 0.04 as of 2026Q1, providing a strong balance sheet buffer that mitigates the risks associated with its current operational volatility and reliance on external biotech funding cycles for revenue growth.
The significant improvement in the current ratio to 7.30 indicates a high level of short-term liquidity, which is essential given the company's exposure to the cyclical nature of the CGT industry. This fortress-like liquidity position provides management with the necessary runway to execute its strategic pivot without the immediate pressure of debt service obligations.
The market frequently misapplies cyclical equipment valuation multiples to BLFS, which obscures the annuity-like, high-margin nature of its proprietary media business and fails to account for the regulatory lock-in that creates a durable, long-term revenue stream independent of the company's historical, capital-intensive hardware manufacturing operations.
Investors should prioritize the 'customer clinical application' count over traditional hardware-based metrics, as the former is a more accurate leading indicator of future commercial-scale demand. Treating the company as a generic life science tool provider ignores the structural barrier to entry that its validated media formulations provide within the CGT manufacturing workflow.
Includes 30+ ratios · 30 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying BLFS stock.
BioLife Solutions, Inc.'s current P/E ratio is -111.7x. The historical average is 6.0x.
BioLife Solutions, Inc.'s return on equity (ROE) is -3.4%. The historical average is -79.3%.
Based on historical data, BioLife Solutions, Inc. is trading at a P/E of -111.7x. Compare with industry peers and growth rates for a complete picture.
BioLife Solutions, Inc. has 64.6% gross margin and -12.6% operating margin.